|Rapid Review complete
|Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.